Neumora Therapeutics Investors Can Join Class Action Lawsuit Over Losses

Neumora Therapeutics Class Action Lawsuit Alert

The law firm Robbins Geller Rudman & Dowd LLP has publicly announced an opportunity for investors in Neumora Therapeutics, Inc. (NASDAQ: NMRA) to participate as lead plaintiffs in a class action lawsuit. This announcement comes as a significant number of people who purchased Neumora's stock during its IPO on September 15, 2023, face considerable financial losses. If you purchased shares during this period, you have until April 7, 2025, to assert your eligibility and charge the company with securities violations.

Overview of the Allegations

Neumora Therapeutics is a clinical-stage biopharmaceutical company focused on creating treatments for brain diseases, including neurodegenerative and neuropsychiatric disorders. The lawsuit stems from allegations that Neumora engaged in misleading practices during its IPO, particularly regarding the disclosure of critical information about its flagship drug candidate, Navacaprant. Investors argue that the IPO's related materials were not only false but also omitted significant risks associated with the company's Phase Three Program.

According to the filings, Neumora altered key trial inclusion criteria, allowing them to present a seemingly favorable outcome for Navacaprant. Specifically, adjustments made to the Phase Two trial included adding patients with moderate to severe major depressive disorder (MDD) to exhibit statistically significant results when that might not have been the case. Furthermore, the Phase Two trials reportedly lacked sufficient data concerning the patient population size and diversity, fundamentally undermining the reliability of the findings presented to investors.

The IPO Details

In the IPO, Neumora sold 14.7 million shares priced at $17 each. Since then, shares have plummeted astonishingly, trading as low as $1.91 per share by February 5, 2025, reflecting a staggering decline of 88.7%. This dramatic shift has caused alarm among shareholders, spurring this class action lawsuit.

The class action, filed under the name Chang v. Neumora Therapeutics, Inc. in the Southern District of New York (Case No. 25-cv-01072), seeks to hold Neumora, its executives, and IPO underwriters accountable for alleged violations of the Securities Act of 1933. If you experienced substantial losses from owning Neumora stock, you could be entitled to compensation.

How to Get Involved

Investors wishing to take part in this legal action can do so by reaching out to Robbins Geller, providing the necessary details regarding their stock purchases. Those who qualify may assume the role of lead plaintiff, working alongside legal representatives to seek justice on behalf of all affected investors. Importantly, potential plaintiffs are not obligated to lead the case to be eligible for any recovery.

About Robbins Geller Rudman & Dowd LLP

Robbins Geller is renowned for its expertise in handling securities fraud cases and has achieved some of the largest recoveries for victims in the industry. With 200 attorneys across 10 offices, the firm has a proven track record of advocating for investors, recovering billions lost through corporate misconduct. Notably, they obtained a record $7.2 billion in a securities class action settlement in the Enron case.

For more information regarding the Neumora class action lawsuit, investors can visit Robbins Geller's website or contact the firm directly at 800-449-4900.

Conclusion

As legal proceedings unfold, affected investors of Neumora Therapeutics are encouraged to explore their options. This class action lawsuit could pave the way for holding the company accountable for any misrepresentations made during the IPO process, providing an avenue for recovering lost investments.